[go: up one dir, main page]

WO2008138578A3 - Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy - Google Patents

Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy Download PDF

Info

Publication number
WO2008138578A3
WO2008138578A3 PCT/EP2008/003789 EP2008003789W WO2008138578A3 WO 2008138578 A3 WO2008138578 A3 WO 2008138578A3 EP 2008003789 W EP2008003789 W EP 2008003789W WO 2008138578 A3 WO2008138578 A3 WO 2008138578A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
devices
treatment
methods
identifying biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/003789
Other languages
French (fr)
Other versions
WO2008138578A2 (en
Inventor
Steen Knudsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allarity Therapeutics AS
Original Assignee
Medical Prognosis Institute AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Prognosis Institute AS filed Critical Medical Prognosis Institute AS
Publication of WO2008138578A2 publication Critical patent/WO2008138578A2/en
Publication of WO2008138578A3 publication Critical patent/WO2008138578A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention features methods, kits, and devices for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying gene biomarkers whose expression correlates to treatment sensitivity or resistance within a patient population or subpopulation.
PCT/EP2008/003789 2007-05-11 2008-05-09 Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy Ceased WO2008138578A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA2007/00714 2007-05-11
DKPA200700714 2007-05-11
DKPA200701023 2007-07-11
DKPA2007/01023 2007-07-11

Publications (2)

Publication Number Publication Date
WO2008138578A2 WO2008138578A2 (en) 2008-11-20
WO2008138578A3 true WO2008138578A3 (en) 2009-03-05

Family

ID=39711924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/003789 Ceased WO2008138578A2 (en) 2007-05-11 2008-05-09 Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy

Country Status (1)

Country Link
WO (1) WO2008138578A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5659014B2 (en) 2007-08-02 2015-01-28 ジリード バイオロジクス，インク． Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis and metastasis
WO2009080437A1 (en) * 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
US8034910B2 (en) 2008-05-06 2011-10-11 Academia Sinica, Taiwan SUMO fusion protein expression system for producing native proteins
JP2012039876A (en) * 2008-12-26 2012-03-01 Univ Of Tokushima Prediction of effectiveness of preoperative chemoradiotherapy on rectal cancer using micro-rna
EP2432896A1 (en) * 2009-05-18 2012-03-28 INSERM - Institut National de la Santé et de la Recherche Médicale A method for predicting the responsiveness of a patient to a treatment with an anti-cd20 antibody and a method for diagnosing rheumatoid arthritis
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP2333103A1 (en) 2009-12-11 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Differential diagnosis and therapy for kinase inhibitors
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
JP2013526852A (en) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Circulating biomarkers for disease
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
MX342405B (en) 2010-06-03 2016-09-28 Pharmacyclics Inc The use of inhibitors of bruton's tyrosine kinase (btk).
JP5755849B2 (en) * 2010-07-06 2015-07-29 東レ株式会社 Composition or kit for determining sensitivity to adjuvant chemotherapy for gastric cancer
US8895509B2 (en) 2010-11-23 2014-11-25 Georgia Tech Research Corporation MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells
DK2532747T3 (en) * 2011-06-09 2016-01-25 Deutsches Krebsforsch Modulators of glycerol-3-phosphate dehydrogenase (GPD2) in therapy
DK3156505T3 (en) * 2011-08-19 2019-08-26 Hummingbird Diagnostics Gmbh COMPLEX SET OF MIRNAs AS NON-INVASIVE BIOMARKERS FOR COLONANCES
US20150148244A1 (en) * 2011-09-08 2015-05-28 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a dihydrofolate reductase inhibitor
BR112015001690A2 (en) 2012-07-24 2017-11-07 Pharmacyclics Inc mutations associated with resistance to bruton tyrosine kinase inhibitors (btk)
EP2898099A4 (en) * 2012-09-21 2016-05-25 Singapore Health Serv Pte Ltd METHOD OF DIAGNOSING LIVER CANCER IN A SUBJECT AND KIT FOR DIAGNOSING LIVER CANCER
CN103784465B (en) * 2012-11-02 2015-11-11 上海交通大学医学院附属瑞金医院 Application of acetaldehyde dehydrogenase 2 as drug target in treatment of tumor cells by anthracycline chemotherapeutic drugs
WO2014108855A1 (en) * 2013-01-10 2014-07-17 Amrita Vishwa Vidyapeetham Differential cerebrospinal fluid reactivity to pfdn5-alpha for detection of b-cell acute lymphoblastic central nervous system leukemia
WO2015192081A1 (en) * 2014-06-13 2015-12-17 Byrd, John C. Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016046640A2 (en) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
KR101674874B1 (en) * 2014-10-21 2016-11-22 한국원자력의학원 Icam-3 as biomarker for the prediction of resistance against anticancer agents and use thereof
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN115612738B (en) * 2022-09-27 2025-12-12 上海爱谱蒂康生物科技有限公司 Biomarker Combinations and Their Application in Predicting Gastric Cancer Treatment Outcomes
AU2024267174A1 (en) 2023-05-08 2025-11-13 Chosa Oncology Ab Liposome compositions and medical uses thereof
WO2025181110A1 (en) * 2024-02-29 2025-09-04 Fondazione Irccs Istituto Nazionale Dei Tumori Prognostic signature for patients suffering from retroperitoneal sarcoma
CN120505416A (en) * 2025-05-08 2025-08-19 中山大学附属第五医院 Application of IV type collagen and encoding gene thereof in prognosis evaluation and treatment of recurrent nasopharyngeal carcinoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAHLEN ANNA ET AL: "Activation of the GLl oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms - Pericytoma with t(7;12)", AMERICAN JOURNAL OF PATHOLOGY, vol. 164, no. 5, May 2004 (2004-05-01), pages 1645 - 1653, XP002494073, ISSN: 0002-9440 *
FOURNIER MARCIA V ET AL: "Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer", CANCER RESEARCH, vol. 66, no. 14, July 2006 (2006-07-01), pages 7095 - 7102, XP002494058, ISSN: 0008-5472 *
KORNMANN MARKO ET AL: "Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 11, 15 September 2003 (2003-09-15), pages 4116 - 4124, XP002391741, ISSN: 1078-0432 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2

Also Published As

Publication number Publication date
WO2008138578A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008138578A3 (en) Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A3 (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2011135459A3 (en) Methods and devices for predicting treatment efficacy
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2012018535A3 (en) Wellness panel
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
BR112014031365A2 (en) methods of detecting disease or conditions
EP2115158A4 (en) DATA PROCESSING, ANALYSIS PROCEDURE FOR GENE EXPRESSION DATA FOR THE IDENTIFICATION OF ENDOGENIC REFERENCE GENES
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2005114190A3 (en) Methods of identifying biomarkers
WO2008154423A3 (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2008134596A3 (en) Use of methylated or unmethylated line-i dna as a cancer marker
PL1977225T3 (en) Electrochemical biosensor analysis system
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
WO2008027428A3 (en) Gene expression profiling for identification, monitoring and treatment of transplant rejection
EP2071025A4 (en) Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same
EP1943353A4 (en) Assay for a health state
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
WO2007047408A3 (en) Promac signature application
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
WO2009007649A3 (en) Device and method for identifying and determining blood groups

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08758461

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08758461

Country of ref document: EP

Kind code of ref document: A2